



Article

Polysulfide and Hydrogen Sulfide Ameliorate Cisplatin-Induced Nephrotoxicity and Renal Inflammation through Persulfidating STAT3 and IKK β

Hai-Jian Sun ¹, Bin Leng ¹ , Zhi-Yuan Wu ^{1,*} and Jin-Song Bian ^{1,2,*}

¹ Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore; phcsunh@nus.edu.sg (H.-J.S.); lengbin@u.nus.edu (B.L.)

² National University of Singapore (Suzhou) Research Institute, Suzhou 215123, China

* Correspondence: phcwzy@nus.edu.sg (Z.-Y.W.); phcbjs@nus.edu.sg (J.-S.B.)

Received: 28 September 2020; Accepted: 20 October 2020; Published: 21 October 2020



Abstract: Cisplatin, a widely used chemotherapy for the treatment of various tumors, is clinically limited due to its extensive nephrotoxicity. Inflammatory response in tubular cells is a driving force for cisplatin-induced nephrotoxicity. The plant-derived agents are widely used to relieve cisplatin-induced renal dysfunction in preclinical studies. Polysulfide and hydrogen sulfide (H₂S) are ubiquitously expressed in garlic, and both of them are documented as potential agents for preventing and treating inflammatory disorders. This study was designed to determine whether polysulfide and H₂S could attenuate cisplatin nephrotoxicity through suppression of inflammatory factors. In renal proximal tubular cells, we found that sodium tetrasulfide (Na₂S₄), a polysulfide donor, and sodium hydrosulfide (NaHS) and GYY4137, two H₂S donors, ameliorated cisplatin-caused renal toxicity through suppression of the massive production of inflammatory cytokines, including tumor necrosis factor α (TNF- α), interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). Mechanistically, the anti-inflammatory actions of Na₂S₄ and H₂S may be mediated by persulfidation of signal transducer and activator of transcription 3 (STAT3) and inhibitor kappa B kinase β (IKK β), followed by decreased phosphorylation of STAT3 and IKK β . Moreover, the nuclear translocation of nuclear transcription factor kappa B (NF- κ B), and phosphorylation and degradation of nuclear factor kappa B inhibitor protein alpha (I κ B α) induced by cisplatin, were also mitigated by both polysulfide and H₂S. In mice, after treatment with polysulfide and H₂S donors, cisplatin-associated renal dysfunction was strikingly ameliorated, as evidenced by measurement of serum blood urea nitrogen (BUN) and creatinine levels, renal morphology, and the expression of renal inflammatory factors. Our present work suggests that polysulfide and H₂S could afford protection against cisplatin nephrotoxicity, possibly via persulfidating STAT3 and IKK β and inhibiting NF- κ B-mediated inflammatory cascade. Our results might shed light on the potential benefits of garlic-derived polysulfide and H₂S in chemotherapy-induced renal damage.

Keywords: cisplatin; hydrogen sulfide; inflammation; STAT3; IKK β

1. Introduction

Cisplatin is a widely used chemotherapeutic agent for the treatment of many solid organ cancers [1]. However, its clinical application for cancer therapy is largely limited because of its several adverse effects, including ototoxicity, neurotoxicity, and nephrotoxicity [2]. Among these side effects, nephrotoxicity is recognized to be most prevalent: accumulative evidence has revealed that over 30% of subjects might suffer from acute kidney injury after treatment with cisplatin [3]. Acute kidney injury is one of the most frequent complications in cancer patients upon cisplatin treatment [4]. As a consequence, the prevention and treatment of cisplatin nephrotoxicity remain a big challenge.

After decades of effort, the pathophysiological mechanisms of cisplatin nephrotoxicity have been identified. Upon cisplatin treatment, the renal proximal tubule cells are more vulnerable to cisplatin-induced cellular damage and later renal dysfunction, since proximal tubule cells have higher expressions of organic cation transporter 2, which may be helpful for them to uptake more cisplatin [5,6]. Mitochondrial dysfunction, reactive oxygen species (ROS) formation, caspase activation, and DNA damage are proposed to be involved in the pathologies of cisplatin-triggered acute kidney injury [7]. Moreover, the inflammation response is also suggested to be a major contributing factor for cisplatin-induced nephrotoxicity as proinflammatory cytokines in the kidneys are observed in significant numbers after administration of cisplatin [8]. Blockade of proinflammatory cytokines is reported to grant protection against cisplatin-induced nephrotoxicity [9]. Accordingly, anti-inflammatory compounds might serve as adjunctive therapies to prevent and treat cisplatin-related nephrotoxicity.

Recent studies have shed significant new lights on the potential strategies for the treatment of cisplatin nephrotoxicity, especially focusing on the renoprotective actions of phytochemicals [5,10]. Importantly, phytochemicals are well established to confer renoprotective effects against cisplatin-induced renal damage without affecting the anticancer efficacy of cisplatin [10,11]. Of these phytochemicals, garlic bioactive substances are found to effectively ameliorate cisplatin nephrotoxicity through anti-inflammatory and antioxidant properties [12,13]. The garlic derivatives are well-known folk remedies for various health issues due to its bioactive constituents, including polysulfide, diallyl trisulfide, and their potential as hydrogen sulfide (H₂S) inducers [14–16]. It is believed that a comprehensive understanding of the roles of polysulfide and H₂S in cisplatin nephrotoxicity will certainly support the use of garlic powders as renoprotective agents in the context of chemotherapy. Actually, we have previously demonstrated that both polysulfide and H₂S not only grant renal protective effects in cisplatin-induced nephrotoxicity, but also greatly increase the anti-cancer sensitivity of cisplatin, suggesting that both of them could serve as attractive drugs for the management of cisplatin nephrotoxicity [17–19]. However, it remains to be investigated whether the protective effects of polysulfide and H₂S on cisplatin-evoked renal damage are associated with the suppression of inflammatory cytokines. The present study was designed to explore the effects of polysulfide and H₂S on cisplatin-elicited nephrotoxicity and renal inflammation. We expected that our present results would provide a basis for the further application of garlic bioactive substances in translational medicine treatment of cisplatin nephrotoxicity through the polysulfide and H₂S signaling pathways.

2. Results

2.1. Polysulfide and H₂S Attenuates Cisplatin-Induced Inflammation in Renal Tubular Cells through Inactivation of Signal Transducer and Activator of Transcription 3 (STAT3) and Inhibitor Kappa B Kinase β (IKK β) Signaling

As renal tubular cell inflammation is closely associated with cisplatin nephrotoxicity (41), the possible roles of exogenous polysulfide and H₂S donors in cisplatin-provoked inflammation were therefore examined in renal tubular cells. The results showed that pretreatment with polysulfide donor sodium tetrasulfide (Na₂S₄), H₂S donors sodium hydrosulfide (NaHS), and GYY4137 clearly diminished the upregulated expressions of tumor necrosis factor α (TNF- α), interleukin-1 β (IL-1 β), IL-6, and cyclooxygenase-2 (COX-2) in renal tubular cells upon cisplatin challenge, as evidenced by Western blotting and RT-PCR analysis (Figure 1A–C).

Subsequently, we examined the possible molecular mechanisms by which polysulfide and H₂S exhibited anti-inflammatory characteristics in renal tubular cells. STAT3 and IKK β are two important transcription factors that play an orchestrated role in cisplatin-induced inflammation response and nephrotoxicity [20,21]. Recent studies have found that H₂S could restrain the activation of STAT3 and IKK β to alleviate inflammation [22,23]. Thus, we speculated that polysulfide and H₂S may have anti-inflammatory effects through suppressing the activation of STAT3 and IKK β in this experimental setting. As shown in Figure 2A,B, cisplatin led to the increased phosphorylation levels of STAT3 and IKK β in renal tubular cells, and these increases were largely abrogated by pretreatment with

polysulfide donor Na₂S₄, H₂S donors NaHS, and GYY4137, further confirming that polysulfide and H₂S were able to inhibit cisplatin-induced renal tubular cell inflammation through inactivation of STAT3 and IKKβ signaling.

Persulfidation (sulfhydrylation) of the specific cysteine residues within proteins is a chemical process that exerts a fundamental role in cellular redox regulation of polysulfide and H₂S [24]. It has been found that H₂S could inactivate IKKβ via persulfidating IKKβ at cysteine 179, thus inhibiting NF-κB activation and the subsequent inflammation response [23]. We recently reported that H₂S directly induced the persulfidation of STAT3 at cysteine 259 and inactivated STAT3-mediated vascular calcification [25]. On the basis of these studies, we examined whether polysulfide and H₂S inhibited the STAT3 and IKKβ signaling pathways via the persulfidation of them. When compared with control treatment, incubation with Na₂S₄ and H₂S donors could significantly promote the persulfidation of STAT3 and IKKβ (Figure 2C,D), suggesting that the sulfhydryl group might be involved in the inhibition of STAT3 and IKKβ induced by either polysulfide or H₂S.




Figure 1. Polysulfide and H₂S attenuated cisplatin-induced inflammation in renal tubular cells. (A) Representative blots of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). (B) Quantitative analysis of TNF-α, IL-1β, IL-6, and COX-2. (C) Relative mRNA levels of TNF-α, IL-1β, IL-6, and COX-2. Data were expressed as mean ± SEM. * *p* < 0.05 vs. Vehicle (Veh), † *p* < 0.05 vs. Cisplatin (Cis). GYY4137 (GYY). *n* = 4–6 in each group.




Figure 2. Both Na₂S₄ and NaHS attenuated the activation of transcription 3 (STAT3) and inhibitor kappa B kinase β (IKKβ) signaling in LLC-PK1 cells treated with cisplatin. (A) Representative blots of P-STAT3 (Phosphorylated STAT3). (B) Representative blots of P-IKKβ (Phosphorylated IKKβ). (C) Representative blots of STAT3 persulfidation. (D) Representative blots of IKKβ persulfidation. (E) Representative blots of nuclear p65 nuclear transcription factor kappa B (NF-κB). (F) Representative blots of cytoplasmic p65 NF-κB. (G) Representative blots of nuclear factor kappa B inhibitor protein alpha (IκBα). (H) Representative blots of P-IκBα (Phosphorylated IκBα). (I) Representative immunofluorescence images of p65 NF-κB. Scale bar = 50 μm. * $p < 0.05$ vs. Vehicle (Veh), † $p < 0.05$ vs. Cisplatin (Cis). GYY4137 (GY). $n = 4-6$ in each group.

2.2. Polysulfide and H₂S Protects Renal Tubular Cells from Cisplatin-Induced Activation of NF-κB Signaling

Studies have shown that cisplatin induces the activation of NF-κB signaling, contributing to subsequent renal tubular cell inflammation and death [26]. The effects of polysulfide and H₂S on NF-κB activation were examined thereafter. The obtained results showed that the nuclear translocation of NF-κB was observed in renal tubular cells upon cisplatin exposure, as reflected by Western blotting, suggesting NF-κB activation in the context of cisplatin (Figure 2E,F). Strikingly, polysulfide and H₂S donors' pretreatment significantly attenuated the nuclear translocation of NF-κB in renal tubular cells induced by cisplatin (Figure 2E,F). Furthermore, the enlargement, degradation, and phosphorylation of IκBα, events for NF-κB activation, were noticeably prevented by both

polysulfide and H₂S in cisplatin-treated cells (Figure 2G,H). Immunofluorescence results further confirmed that cisplatin-induced nuclear deposition of NF-κB in renal tubular cells was evidently prevented in the presence of polysulfide and H₂S donors (Figure 2I).

Importantly, pharmacological inhibition of STAT3, IKKβ, and NF-κB with their specific inhibitors almost completely blocked the protein and mRNA expressions of TNF-α, IL-1β, IL-6, and COX-2 in cisplatin-incubated renal tubular cells (Figure 3A–E), indicating the critical involvement of STAT3/IKKβ/NF-κB signaling loop in cisplatin-mediated renal inflammation.




Figure 3. Pharmacological inhibition of STAT3, IKKβ, and NF-κB with their specific inhibitors prevented cisplatin (Cis)-induced inflammation in renal tubular cells. (A–D) Representative blots and quantitative analysis of TNF-α, IL-1β, IL-6, and COX-2. (E) Relative mRNA levels of TNF-α, IL-1β, IL-6, and COX-2. * *p* < 0.05 vs. Vehicle (Veh), † *p* < 0.05 vs. Control (Con). Cisplatin (Cis). *n* = 4–6 in each group.

2.3. Polysulfide and H₂S Ameliorates Cisplatin-Induced Renal Dysfunction and Inflammation in Mice

To explore the renal protective effects of polysulfide and H₂S, the pathological changes in renal tissues and renal function parameters were investigated in a mouse model of cisplatin nephrotoxicity. In agreement with our previous report [17], the renal sections of periodic acid-Schiff (PAS) staining exhibited obvious features of tubular injury in cisplatin-induced mice, while these pathological changes were obviously ameliorated by polysulfide donor Na₂S₄, H₂S donors NaHS, and GYY4137 (Figure 4A). In line with the ameliorated renal morphology, the elevated serum BUN and creatinine levels in cisplatin-treated mice were remarkably reversed by both polysulfide and H₂S donors (Figure 4B,C).




Figure 4. Polysulfide and H₂S attenuated cisplatin-induced nephrotoxicity in mice. (A) Periodic acid-Schiff (PAS) staining of renal sections. Scale bar = 100 μm. (B) Serum blood urea nitrogen (BUN) levels. (C) Serum creatinine levels. * $p < 0.05$ vs. Vehicle (Veh), † $p < 0.05$ vs. Cisplatin (Cis). GYY4137 (GYY). $n = 5$ in each group.

Moreover, the therapeutic effects of polysulfide and H₂S on cisplatin-induced inflammation response were also assessed in mice as inflammation is critically involved in the pathologies of cisplatin nephrotoxicity [27]. As previously described [28,29], the levels of TNF- α and IL-1 β in both serum and renal tissues were significantly enhanced in cisplatin-induced mice, and these upregulated pro-inflammatory cytokines were diminished by Na₂S₄, NaHS, and GYY4137 (Figure 5A–B). Then, we conducted RT-PCR and immunoblot to testify the expressions of pro-inflammatory cytokines in renal tissues, including TNF- α , IL-1 β , IL-6, and COX-2. In the presence of Na₂S₄, NaHS, and GYY4137, the lower mRNA and protein levels of TNF- α , IL-1 β , IL-6, and COX-2 in renal tissues were found when compared with the cisplatin group (Figure 5C–E). Macrophage marker F4/80 staining results further showed that both polysulfide and H₂S could effectively attenuate cisplatin-induced renal inflammation (Figure 5F). These findings suggest an anti-inflammatory role of polysulfide and H₂S in cisplatin nephrotoxicity.




Figure 5. Polysulfide and H₂S attenuated cisplatin-induced renal inflammation. (A) Serum levels of TNF- α and IL-1 β . (B) Renal levels of TNF- α and IL-1 β . (C) Representative blots of TNF- α , IL-1 β , IL-6, and COX-2 in renal tissues. (D) Quantitative analysis of TNF- α , IL-1 β , IL-6, and COX-2. (E) Relative mRNA levels of TNF- α , IL-1 β , IL-6, and COX-2. (F) Representative immunofluorescence staining of macrophage marker F4/80. Scale bar = 20 μ m. * $p < 0.05$ vs. Vehicle (Veh), † $p < 0.05$ vs. Cisplatin (Cis). GYY4137 (GYY). $n = 5$ in each group.

2.4. Polysulfide and H₂S Attenuates the Activation of STAT3, IKK β , and NF- κ B Signaling in Cisplatin-Induced Kidneys

We further examined the effects of polysulfide and H₂S on STAT3, IKK β , and NF- κ B activation in mouse renal tissues after administration of cisplatin. Similar to the results from cell experiments, cisplatin treatment led to higher phosphorylation levels of STAT3 and IKK β in conjunction with NF- κ B nuclear translocation in renal tissues, effects that were significantly mitigated by polysulfide and H₂S donors (Figure 6A–D). Similarly, the phosphorylation and degradation of I κ B α appeared to be higher in cisplatin-induced kidneys, which was markedly prevented by both polysulfide and H₂S (Figure 6E,F). These results collectively indicate that polysulfide and H₂S strongly inhibited STAT3/IKK β /NF- κ B-dependent release of pro-inflammatory cytokines in renal tissues from cisplatin-induced mice.




Figure 6. Polysulfide and H₂S attenuated the activation of STAT3 and IKKβ in mice after cisplatin treatment. (A) Representative blots of P-STAT3. (B) Representative blots of P-IKKβ. (C) Representative blots of nuclear p65 NF-κB. (D) Representative blots of cytoplasmic p65 NF-κB. (E) Representative blots of IκBα. (F) Representative blots of P-IκBα. * $p < 0.05$ vs. Vehicle (Veh), † $p < 0.05$ vs. Cisplatin (Cis). GYY4137 (GYY). $n = 5$ in each group.

3. Discussion

Nephrotoxicity is one of the main side effects in cisplatin chemotherapy, thus limiting its clinical application for the treatment of cancer patients. This drives us to discover the novel reagents or chemicals that could prevent renal tubular cell injury induced by cisplatin without affecting the anti-tumor properties of cisplatin. As the two most abundant chemicals in garlic, polysulfide and H₂S contribute to the clinical benefits of garlic derivatives in the context of various diseases [30,31]. Our present results demonstrated that polysulfide and H₂S could be used for the management of cisplatin nephrotoxicity through inhibiting renal inflammation. Mechanistically, both polysulfide and H₂S induced the persulfidation of STAT3 and IKKβ, two transcriptional factors involved in inflammation response [32], leading to STAT3 and IKKβ dephosphorylation. Moreover, the classical IKKβ-dependent NF-κB signaling pathway in cisplatin nephrotoxicity was also largely suppressed by administration of polysulfide and H₂S donors. These results collectively demonstrated that both polysulfide and H₂S could be employed as anti-inflammatory drugs to relieve cisplatin-induced nephrotoxicity. We also provide a possible clue that garlic's organopolysulfide and H₂S-releasing activity could promote health benefits through their strong anti-inflammatory activities.

The entrance of cisplatin into renal proximal tubular cells activates the apoptotic pathways and induces cellular damage via both oxidative stress and inflammation response [33]. The overproduction of inflammatory factors is one of the driving forces for renal proximal tubular cell death upon cisplatin treatment [34], while both polysulfide and H₂S are well documented to exert anti-inflammatory effects [35,36]. We therefore examined the effects of polysulfide and H₂S on cisplatin-induced inflammation response in renal proximal tubular cells. Our finding supported the notion that both polysulfide and H₂S protected renal proximal tubular cells against inflammation response, as evidenced by measurement of TNF-α, IL-1β, IL-6, and COX-2. The direct anti-inflammatory effects of polysulfide

and H₂S may account for their anti-apoptotic effects on renal proximal tubular cells induced by cisplatin, and this had been demonstrated by our previous reports [17,19]. The protective effects of polysulfide and H₂S were further demonstrated in animal models with cisplatin nephrotoxicity. We found that renal dysfunction and renal morphological changes in cisplatin-induced mice were markedly ameliorated by polysulfide and H₂S donors together with attenuation of renal inflammation. The anti-inflammatory effects of polysulfide and H₂S in animals were consistent with the cell culture experiments. Both *in vivo* and *in vitro* evidence suggested a potential of polysulfide and H₂S in treating cisplatin nephrotoxicity associated with anti-inflammatory activities.

Thereafter, we explored the underlying mechanisms whereby polysulfide and H₂S exerted anti-inflammatory effects on renal proximal tubular cells. The implications of STAT3 and IKK β were examined because of their critical roles in the development of cisplatin-induced renal inflammation [37,38]. Similar to previous reports [20,39], cisplatin treatment led to higher phosphorylation levels of STAT3 and IKK β , which were strikingly suppressed by polysulfide and H₂S donors in renal proximal tubular cells. Importantly, inhibition of either STAT3 or IKK β with their individual inhibitors attenuated cisplatin-induced upregulations of inflammatory factors, further confirming the critical engagement of the STAT3 and IKK β pathway in cisplatin-induced renal inflammation.

We then investigated how polysulfide and H₂S inhibited the phosphorylation of STAT3 and IKK β in response to cisplatin. S-nitrosylation, a redox-based modification of protein thiols, has recently been recognized as nitric oxide (NO)-dependent cellular signal transduction mechanism [40], and it has been found that S-nitrosylation of STAT3 at cysteine 259 is crucial for inhibition of STAT3 transactivation-mediated inflammation [41]. Likewise, cysteine 179 within IKK β is a main target for S-nitrosylation, thus contributing to anti-inflammatory effects of NO [42]. On these grounds, we hypothesized that polysulfide and H₂S might lead to inactivation of STAT3 and IKK β by the persulfidation of these proteins. The results showed that polysulfide and H₂S donors obviously promoted the persulfidation of STAT3 and IKK β using a tag-switch assay, indicating a possible interaction between organic sulfides and STAT3/IKK β . These findings demonstrated that STAT3 and IKK β are important targets for the redox regulation of polysulfide and H₂S, thus providing a novel mechanism for their anti-inflammatory properties.

IKK β is an important catalytic subunit for NF- κ B activation, and NF- κ B activation is involved in the upregulated expressions of various inflammatory cytokines and chemokines [43]. Indeed, cisplatin itself induces activation of NF- κ B and its nuclear translocation is responsible for the production and release of inflammatory cytokines in renal proximal tubular cells [44]. The phosphorylation and degradation of I κ B α is an upstream event for nuclear translocation and activation of NF- κ B [45,46]. As such, interest in the treatment of cisplatin nephrotoxicity by targeting the NF- κ B pathway has greatly increased due to its pathogenic roles in renal inflammation and damage. Here, we found that increased nuclear accumulation of NF- κ B, phosphorylation, and degradation of I κ B α were significantly inhibited by polysulfide and H₂S donors in either cisplatin-treated renal proximal tubular cells or cisplatin-challenged kidneys from mice. These results collectively suggested that polysulfide and H₂S granted a protection against cisplatin-induced nephrotoxicity through inhibiting NF- κ B-mediated renal inflammation. This is in-keeping with a notion that both polysulfide and H₂S are recognized as novel inhibitors of NF- κ B [47,48].

In our previous reports [19], cisplatin administration led to a significant reduction in plasma H₂S levels in animals, and this is in conjunction with reduced CSE expression in renal cortex tissues. Interestingly, the expression level of CBS in renal cortex remains unaltered in animals after administration of cisplatin [19]. Our previous findings suggest that administration of cisplatin results in the reduction of endogenous H₂S production, which may be ascribed to the downregulated expressions of CSE in renal cortex [19]. In the present study, we demonstrated that polysulfide and H₂S donors were effective in ameliorating renal dysfunction in a mouse model of cisplatin nephrotoxicity. It remains to be investigated whether the protective effects of polysulfide and H₂S donors on cisplatin-induced renal damage are associated with the changes in plasma H₂S levels or renal CBS/CSE expressions in

mouse when treated with such donors. Therefore, the present investigation has limitations inherent to any integrative *in vivo* studies because the exact fate of polysulfide and H₂S donors and their cellular interactions cannot be clarified. Regardless, it is necessary to measure the plasma H₂S levels and renal CBS/CSE expressions in mice after administration of polysulfide and H₂S donors, since such measurements are vital for a better understanding of their biological activities. In our future studies, the pharmacokinetics of polysulfide and H₂S donors in animals and their effects on renal CBS/CSE expressions will be comprehensively explored.

After reviewing the published literatures, inconsistent results are observed with respect to the effects of H₂S on cisplatin-induced nephrotoxicity. In a previously published paper [49], the authors found that application of GYY4137 further aggravated renal inflammation, oxidative stress, apoptotic response, and renal dysfunction in mice following cisplatin treatment. The discrepancy may result from the different preparation and dosages of GYY4137 used between the previous study and our present research. GYY4137 was prepared and stored in DMSO: PEG solution (1:1) by Liu and colleagues [49]. Nevertheless, it is well known that DMSO might accelerate the decomposition of GYY4137 [50]. Importantly, GYY4137 could be easily dissolved in water and a toxic solvent like DMSO might be unnecessary [50]. Moreover, Liu and colleagues used GYY4137 at a low dose of GYY4137 (21 mg/kg) in mice, and it is highly probable that H₂S might be insufficiently provided at lower concentrations considering the H₂S release characteristics of GYY4137 [51–53]. On these grounds, a commonly used dose of GYY4137 (100 mg/kg; dissolved in PBS) was prepared in our animal studies, and GYY4137 largely ameliorated cisplatin-induced renal dysfunction and damage, which is in-keeping with the results of NaHS (another H₂S donor) application in animals [54–56]. These results clearly demonstrated the protective actions of H₂S donors against cisplatin-induced nephrotoxicity.

Similar to the notion from Yang's group [49], Francescato et al., have found that DL-propargylglycine (PAG), an inhibitor of endogenous H₂S formation, reduces renal damage in rats induced by cisplatin [57]. In this study, an increased H₂S generation rate and CSE expression were observed in the outer medulla from cisplatin-injected rats [57]. By contrast, exogenous H₂S donors, NaHS, and sodium thiosulfate (STS) were found to protect against both cisplatin- and gentamicin-induced nephrotoxicity [54,58–60]. These conflicting results might be derived from a fact that PAG might be a non-specific inhibitor of CSE and also affects the functions of other enzymes that may play a central role in renal cellular responses to cisplatin. This viewpoint may be supported by the findings from the same group that treatment with increasing concentrations of NaHS had no effect on renal tubular cell survival, causing doubt about whether PAG is only inhibiting H₂S production in this case [57]. Additionally, many studies have confirmed that endogenous H₂S is protective against renal ischemia-reperfusion injury [61–64], renal fibrosis [65–67], and diabetic nephropathy [68,69]. In response to ischemia, H₂S levels are diminished along with renal dysfunction, and inhibition of CBS leads to accumulation of homocysteine and renal ischemia-reperfusion injury [70,71]. In this regard, it is hard to give a clear unified view on these conflicting results, and the precise roles of endogenous or exogenous H₂S in cisplatin-induced renal injury deserve further evaluation. Future research on the measurement of cellular sulfide levels during cisplatin-induced nephrotoxicity will be helpful to shed light on these contradicting findings. Furthermore, newly synthesized H₂S donors or inhibitors will produce a better understanding of their exact roles as a renal protective molecule.

In conclusion, our findings suggest that the beneficial effects of polysulfide and H₂S on cisplatin nephrotoxicity could be mainly due to their anti-inflammatory actions, especially in proximal tubular cells. The molecular mechanisms analysis showed that polysulfide and H₂S ameliorated cisplatin nephrotoxicity by persulfidation and inactivation of STAT3 and IKK β , as well as inhibition of NF- κ B signaling. These results indicated that both polysulfide and H₂S could serve as effective anti-inflammatory remedies for preventing and treating cisplatin nephrotoxicity. In light of the abundance of sulfur constituents in garlic, including polysulfide and H₂S, this study may highlight the tremendous benefits of edible plants like garlic in cisplatin nephrotoxicity.

4. Materials and Methods

4.1. Reagents and Chemicals

Polysulfide donor Na_2S_4 was purchased from Dojindo Molecular Technologies Dojindo (Kumamoto, Japan). Cisplatin and NaHS were bought from Sigma-Aldrich (St. Louis, MO, USA). GYY4137 was synthesized as we previously depicted [72]. A selective and reversible inhibitor of $\text{IKK}\beta$ (IKK-2), SC-514, was procured from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). A selective STAT3 inhibitor HO-3867 was obtained from Medchem express (Princeton, NJ, USA). Antibodies against IL-6, COX-2, F4/80, Biotin, Lamin B1, and β -actin, and the secondary antibodies, were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibodies against TNF- α , IL-1 β , phosphorylated and total I κ B α , NF- κ B, phosphorylated and total STAT3, and phosphorylated and total IKK β were obtained from Abcam (Cambridge, MA, USA). Dulbecco's modified Eagle's medium (DMEM), streptomycin/penicillin, trypsin, and fetal bovine serum (FBS) were provided by Hyclone Laboratories (South Logan, UT, USA). The radio-immunoprecipitation assay (RIPA) lysis buffer was purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Goat anti-mouse IgG (H+L) Highly Cross-Adsorbed Alexa Fluor 594 Secondary Antibody was procured from Invitrogen (Carlsbad, CA, USA). The specific primers used in this study were synthesized by Integrated DNA Technologies (Singapore).

4.2. Animals

All animal experimental procedures were approved by Institutional Animals Care and Use Committee at National University of Singapore. During the process of animal experiments, the animals were subject to humane care in accordance with the criteria of the Care and Use of Laboratory Animal published by the US National Institutes of Health (National Institutes of Health publication, 8th edition, 2011). A total of 6–8 week male C57BL/6 mice were used to study the therapeutic effects of H_2S and polysulfide on cisplatin nephrotoxicity. In detail, all mice were randomly divided into five groups (five mice for each group), including control group, cisplatin group, NaHS+cisplatin group, GYY4137+cisplatin group, and Na_2S_4 +cisplatin group. NaHS (5.6 mg/kg, dissolved in normal PBS), GYY4137 (100 mg/kg, dissolved in PBS), and Na_2S_4 (500 $\mu\text{g}/\text{kg}$, dissolved in normal PBS) were administrated to mice by intraperitoneal injection a total of four times (once a day). After the second injection of these compounds for 30 min, cisplatin (25 mg/kg) was given by a single intraperitoneal injection. The control mice received normal PBS by intraperitoneal injection for 4 days. After the last time these agents were injected for 24 h, the blood samples and renal tissues were collected when animals were sacrificed. The blood samples and partial kidney tissues were stored at -80°C for biochemical analysis. The remaining renal tissues were fixed in 4% paraformaldehyde for histology examination.

4.3. Histology Analysis and Immunofluorescence

To assess the renal morphology, the renal sections (5 μm) were subject to PAS staining. The stained sections were visualized under a light microscope (Leica, Microsystems, Germany). A total of six fields in each section were captured for the evaluation of pathological damage in-keeping with previous studies [28]. For immunofluorescent staining of F4/80, the renal sections were incubated with 5% serum for 60 min after dewaxing and rehydrating, and the sections were probed with anti-F4/80 antibody. The renal sections were then incubated with goat anti-mouse Alexa Fluor 594 antibody for 1 h at 37°C . The nucleus was stained with 4',6-diamidino-2-phenylindole (DAPI), and the images were obtained by a fluorescence microscope (Leica, Heidelberg, Germany).

4.4. Enzyme-Linked Immunosorbent Assay (ELISA)

The levels of TNF- α and IL-1 β in the serum and renal tissues were measured by commercial ELISA kits (BOSTER, Wuhan, China) following the manufacturer's protocols [73,74]. The renal levels of TNF- α and IL-1 β were normalized to protein contents in each sample.

4.5. Assessment of Renal Function

At the end of animal experiments, the serum samples were collected and the serum BUN and creatinine levels were measured to evaluate kidney function by using commercially available kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) in accordance with the manufacturer's protocols [29,75]. The absorbance for serum BUN was analyzed at 640 nm by a microplate reader. The optical density was read at 546 nm for serum creatinine measurement using a Varioskan Flash microplate reader (Waltham, MA, USA).

4.6. Cell Culture and Treatment

LLC-PK1 cells, a porcine renal proximal tubular cell line (ATCC, Manassas, VA, USA), were cultured in DMEM containing 10% FBS, 1% penicillin, and streptomycin, under an environment with 95% air and 5% CO₂ at 37 °C. After the cells achieved 80% confluence, the cells were passaged at a ratio of 1:3. To test the protective effects of H₂S and polysulfide on cisplatin-induced renal toxicity, LLC-PK1 cells were pretreated with Na₂S₄ (80 μM), NaHS (100 μM), and GYY4137 (600 μM), for 30 min, and then were stimulated with cisplatin (30 μM) for 24 h. To examine the involvement of the STAT3 and IKKβ in cisplatin-triggered LLC-PK1 cell toxicity, HO-3867 (5 μM) and SC-514 (50 μM) were pre-added individually to the culture medium for 30 min before cisplatin (30 μM) treatment for 24 h.

4.7. Immunofluorescence Staining

After fixation and permeabilization, the cells were incubated with p65 NF-κB antibody overnight at 4 °C. The cells were then incubated with goat anti-mouse IgG (H + L) Highly Cross-Adsorbed Alexa Fluor 488 Secondary Antibody (1:200) for 30 min. Nuclei were counterstained with DAPI. Immunofluorescence signals were obtained using a fluorescence microscope (Leica, Heidelberg, Germany).

4.8. Western Blot Analysis

The dissected renal tissues or cultured cells were prepared for sequential extraction of proteins. The nuclear and cytoplasmic proteins were extracted as we previously described [17]. These samples were lysed in RIPA buffer, and the protein contents in each sample were determined by bicinchoninic acid (BCA) colorimetric protein kit (Pierce, MO, USA). The same amount of protein levels was loaded onto the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and then transferred to polyvinylidene fluoride (PVDF) membranes. After blocking in 5% skim milk at room temperature for 1 h, the membranes were probed with the required primary antibodies overnight at 4 °C. After that, these membranes were incubated with the corresponding secondary antibodies linked with horseradish peroxidase for 1 h. The positive bands on the membranes were visualized by enhanced chemiluminescence (ECL) substrate in BioRad ChemiDoc XRS system (Bio-RAD), and the density of the indicated bands was normalized to the levels of housekeeping gene on the same membrane.

4.9. S-Sulphydration Assay

S-sulphydration of STAT3 and IKKβ was measured by a tag-switch method [19,22]. In short, the collected cells were dissolved in HEN buffer (250 mM HEPES, 50 mM NaCl, 1 mM EDTA, 0.1 mM neocuproine, 1% NP-40). Cell lysates were incubated with a water-soluble methylsulfonyl benzothiazole (MSBT-A, 50 mM) at 37 °C for 1h. After salt removal, the mixture was added into anti-STAT3 antibody (2 μg) or anti-IKKβ antibody (2 μg) containing protein A/G beads overnight at 4 °C, respectively. The beads were then washed by PBS three times and resuspended in biotin-linked cyanoacetate (20 mM) at 37 °C for 1h under gentle shaking conditions. After centrifugation, biotinylated protein was pulled down by streptavidin magnet beads and eluted by SDS-PAGE loading buffer (30 μL), and the samples were further detected by Western blot. S-sulphydrated STAT3 and IKKβ expressions were determined by using anti-biotin antibody.

4.10. Quantitative Real-Time PCR

After the isolation of total mRNA and cDNA synthesis, Synergy Brands Synergy Brands (SYBR) green-based (Promega, A6001) real-time PCR amplification was conducted under real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. The mRNA levels of the target genes were quantified using the $2^{-\Delta\Delta C_t}$ method and normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The specific sequences of used primers in the present study were listed in Tables S1 and S2.

4.11. Statistical Analysis

The results were expressed as mean \pm SEM. Unpaired *t*-test was used to compare one variable within two groups. ANOVA was applied to compare one variable in three or more groups followed by Bonferroni's multiple comparisons test. Differences with a *p*-value of less than 0.05 were predetermined as the threshold for statistical significance.

Supplementary Materials: Supplementary Materials can be found at <http://www.mdpi.com/1422-0067/21/20/7805/s1>.

Author Contributions: Conceptualization, J.-S.B., and H.-J.S.; Data curation, J.-S.B.; Formal analysis, H.-J.S., B.L.; Investigation, H.-J.S., and B.L.; Methodology, Z.-Y.W.; Project administration, H.-J.S., B.L., and Z.-Y.W.; Writing—original draft, Z.-Y.W., and H.-J.S.; Writing, review and editing, J.-S.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Ministry of Education of Singapore Tier 2 Research grant (MOE2017-T2-2-029) and Jiangsu Nature Science Foundation, China (BK20181185).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

BUN	blood urea nitrogen
COX-2	cyclooxygenase-2
DAPI	4',6-diamidino-2-phenylindole
ELISA	enzyme-linked immunosorbent assay
FBS	fetal bovine serum
H ₂ S	hydrogen sulfide
IL-1 β	interleukin-1 β
IL-6	interleukin-6
I κ B α	nuclear factor kappa B inhibitor protein alpha
I κ K β	inhibitor kappa B kinase β
NaHS	sodium hydrosulfide
NF- κ B	nuclear transcription factor kappa B
NO	nitric oxide
PAG	DL-propargylglycine
PAS	periodic acid-Schiff
ROS	reactive oxygen species
STAT3	signal transducer and activator of transcription 3
STS	sodium thiosulfate
TNF- α	tumor necrosis factor α

References

1. Lajous, H.; Lelièvre, B.; Vauléon, E.; LeComte, P.; Garcion, E. Rethinking Alkylating(-Like) Agents for Solid Tumor Management. *Trends Pharmacol. Sci.* **2019**, *40*, 342–357. [[CrossRef](#)] [[PubMed](#)]
2. Florea, A.M.; Büsselberg, D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. *Cancers* **2011**, *3*, 1351–1371. [[CrossRef](#)] [[PubMed](#)]

3. Ries, F.; Klustersky, J. Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity. *Am. J. Kidney Dis.* **1986**, *8*, 368–379. [[CrossRef](#)]
4. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.* **2005**, *4*, 307–320. [[CrossRef](#)]
5. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. *Kidney Int.* **2008**, *73*, 994–1007. [[CrossRef](#)]
6. Pabla, N.; Murphy, R.F.; Liu, K.; Dong, Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. *Am. J. Physiol. Physiol.* **2009**, *296*, F505–F511. [[CrossRef](#)]
7. Holditch, S.J.; Brown, C.N.; Lombardi, A.M.; Nguyen, K.N.; Edelman, C.L. Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury. *Int. J. Mol. Sci.* **2019**, *20*, 3011. [[CrossRef](#)]
8. Oh, G.S.; Kim, H.J.; Choi, J.H.; Shen, A.; Choe, S.K.; Karna, A.; Lee, S.H.; Jo, H.J.; Yang, S.H.; Kwak, T.H.; et al. Pharmacological activation of NQO1 increases NAD⁺ levels and attenuates cisplatin-mediated acute kidney injury in mice. *Kidney Int.* **2014**, *85*, 547–560. [[CrossRef](#)]
9. Ozkok, A.; Edelman, C.L. Pathophysiology of Cisplatin-Induced Acute Kidney Injury. *BioMed Res. Int.* **2014**, *2014*, 1–17. [[CrossRef](#)]
10. Ojha, S.; Venkataraman, B.; Kurdi, A.; Mahgoub, E.; Sadek, B.; Rajesh, M. Plant-Derived Agents for Counteracting Cisplatin-Induced Nephrotoxicity. *Oxidative Med. Cell. Longev.* **2016**, *2016*, 1–27. [[CrossRef](#)]
11. Sun, C.Y.; Zhang, Q.Y.; Zheng, G.J.; Feng, B. Phytochemicals: Current strategy to sensitize cancer cells to cisplatin. *Biomed. Pharmacother.* **2019**, *110*, 518–527. [[CrossRef](#)] [[PubMed](#)]
12. Razo-Rodriguez, A.C.; Chirino, Y.I.; Sánchez-González, D.J.; Martínez-Martínez, C.M.; Cruz, C.; Pedraza-Chaverri, J. Garlic Powder Ameliorates Cisplatin-Induced Nephrotoxicity and Oxidative Stress. *J. Med. Food* **2008**, *11*, 582–586. [[CrossRef](#)] [[PubMed](#)]
13. Abdel-Daim, M.M.; Abdel-Rahman, H.G.; Dessouki, A.A.; El-Far, A.H.; Khodeer, D.M.; Bin-Jumah, M.; Alhader, M.S.; Alkahtani, S.; Aleya, L. Impact of garlic (*Allium sativum*) oil on cisplatin-induced hepatorenal biochemical and histopathological alterations in rats. *Sci. Total. Environ.* **2020**, *710*, 136338. [[CrossRef](#)]
14. Mani, S.; Cao, W.; Wu, L.; Wang, R. Hydrogen sulfide and the liver. *Nitric Oxide* **2014**, *41*, 62–71. [[CrossRef](#)]
15. Rodrigues, C.; Percival, S.S. Immunomodulatory Effects of Glutathione, Garlic Derivatives, and Hydrogen Sulfide. *Nutrients* **2019**, *11*, 295. [[CrossRef](#)] [[PubMed](#)]
16. Yagdi, E.; Cerella, C.; Dicato, M.; Diederich, M. Garlic-derived natural polysulfanes as hydrogen sulfide donors: Friend or foe? *Food Chem. Toxicol.* **2016**, *95*, 219–233. [[CrossRef](#)] [[PubMed](#)]
17. Cao, X.; Nie, X.; Xiong, S.; Cao, L.; Wu, Z.; Moore, P.K.; Bian, J.S. Renal protective effect of polysulfide in cisplatin-induced nephrotoxicity. *Redox Biol.* **2018**, *15*, 513–521. [[CrossRef](#)] [[PubMed](#)]
18. Cao, X.; Zhang, W.; Moore, P.K.; Bian, J.S. Protective Smell of Hydrogen Sulfide and Polysulfide in Cisplatin-Induced Nephrotoxicity. *Int. J. Mol. Sci.* **2019**, *20*, 313. [[CrossRef](#)]
19. Cao, X.; Xiong, S.; Zhou, Y.; Wu, Z.; Ding, L.; Zhu, Y.; Wood, M.E.; Whiteman, M.; Moore, P.K.; Bian, J.S. Renal Protective Effect of Hydrogen Sulfide in Cisplatin-Induced Nephrotoxicity. *Antioxid. Redox Signal.* **2018**, *29*, 455–470. [[CrossRef](#)]
20. Sun, C.Y.; Nie, J.; Zheng, Z.L.; Zhao, J.; Wu, L.M.; Zhu, Y.; Su, Z.Q.; Zheng, G.; Feng, B. Renoprotective effect of scutellarin on cisplatin-induced renal injury in mice: Impact on inflammation, apoptosis, and autophagy. *Biomed. Pharmacother.* **2019**, *112*, 108647. [[CrossRef](#)]
21. Ma, X.; Dang, C.; Kang, H.; Dai, Z.J.; Lin, S.; Guan, H.; Liu, X.; Wang, X.J.; Hui, W. Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF- κ B signalling pathways. *Int. Immunopharmacol.* **2015**, *28*, 399–408. [[CrossRef](#)] [[PubMed](#)]
22. Cao, L.; Cao, X.; Zhou, Y.; Nagpure, B.V.; Wu, Z.Y.; Hu, L.F.; Yang, Y.; Sethi, G.; Moore, P.K.; Bian, J.S. Hydrogen sulfide inhibits ATP-induced neuroinflammation and A β 1–42 synthesis by suppressing the activation of STAT3 and cathepsin S. *Brain Behav. Immun.* **2018**, *73*, 603–614. [[CrossRef](#)] [[PubMed](#)]
23. Zhang, D.; Wang, X.; Chen, S.; Chen, S.; Yu, W.; Liu, X.; Yang, G.; Tao, Y.; Tang, X.; Bu, D.; et al. Endogenous hydrogen sulfide sulfhydrates IKK β at cysteine 179 to control pulmonary artery endothelial cell inflammation. *Clin. Sci.* **2019**, *133*, 2045–2059. [[CrossRef](#)] [[PubMed](#)]
24. Kimura, H. Hydrogen Sulfide and Polysulfide Signaling. *Antioxid. Redox Signal.* **2017**, *27*, 619–621. [[CrossRef](#)]

25. Zhou, Y.B.; Zhou, H.; Li, L.; Kang, Y.; Cao, X.; Wu, Z.Y.; Ding, L.; Sethi, G.; Bian, J.S. Hydrogen Sulfide Prevents Elastin Loss and Attenuates Calcification Induced by High Glucose in Smooth Muscle Cells through Suppression of Stat3/Cathepsin S Signaling Pathway. *Int. J. Mol. Sci.* **2019**, *20*, 4202. [[CrossRef](#)]
26. Michel, H.E.; Menze, E.T. Tetramethylpyrazine guards against cisplatin-induced nephrotoxicity in rats through inhibiting HMGB1/TLR4/NF- κ B and activating Nrf2 and PPAR- γ signaling pathways. *Eur. J. Pharmacol.* **2019**, *857*, 172422. [[CrossRef](#)]
27. Volarevic, V.; Djokovic, B.; Jankovic, M.G.; Harrell, C.R.; Fellabaum, C.; Djonov, V.; Arsenijevic, N. Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. *J. Biomed. Sci.* **2019**, *26*, 1–14. [[CrossRef](#)]
28. Yu, X.; Meng, X.; Xu, M.; Zhang, X.; Zhang, Y.; Ding, G.; Huang, S.; Zhang, A.; Jia, Z. Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-kappaB and improving mitochondrial function. *EBioMedicine* **2018**, *36*, 266–280. [[CrossRef](#)]
29. Lu, Q.B.; Du, Q.; Wang, H.P.; Tang, Z.H.; Wang, Y.B.; Sun, H.J. Salusin-beta mediates tubular cell apoptosis in acute kidney injury: Involvement of the PKC/ROS signaling pathway. *Redox Biol.* **2020**, *30*, 101411. [[CrossRef](#)]
30. Rose, P.; Moore, P.K.; Zhu, Y.Z. Garlic and Gaseous Mediators. *Trends Pharmacol. Sci.* **2018**, *39*, 624–634. [[CrossRef](#)]
31. Tocmo, R.; Wu, Y.; Liang, D.; Fogliano, V.; Huang, D. Boiling enriches the linear polysulfides and the hydrogen sulfide-releasing activity of garlic. *Food Chem.* **2017**, *221*, 1867–1873. [[CrossRef](#)] [[PubMed](#)]
32. He, G.; Karin, M. NF- κ B and STAT3—key players in liver inflammation and cancer. *Cell Res.* **2010**, *21*, 159–168. [[CrossRef](#)]
33. Manohar, S.; Leung, N. Cisplatin nephrotoxicity: A review of the literature. *J. Nephrol.* **2017**, *31*, 15–25. [[CrossRef](#)] [[PubMed](#)]
34. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin Nephrotoxicity. *Toxins* **2010**, *2*, 2490–2518. [[CrossRef](#)] [[PubMed](#)]
35. Miltonprabu, S.; Sumedha, N.; Senthilraja, P. RETRACTED: Diallyl trisulfide, a garlic polysulfide protects against As-induced renal oxidative nephrotoxicity, apoptosis and inflammation in rats by activating the Nrf2/ARE signaling pathway. *Int. Immunopharmacol.* **2017**, *50*, 107–120. [[CrossRef](#)] [[PubMed](#)]
36. Bęłtowski, J. Hydrogen sulfide in pharmacology and medicine—An update. *Pharmacol. Rep.* **2015**, *67*, 647–658. [[CrossRef](#)]
37. Sen, Z.; Jie, M.; Jingzhi, Y.; Dongjie, W.; Dongming, Z.; Xiaoguang, C. Total Coumarins from *Hydrangea paniculata* Protect against Cisplatin-Induced Acute Kidney Damage in Mice by Suppressing Renal Inflammation and Apoptosis. *Evidence-Based Complement. Altern. Med.* **2017**, *2017*, 1–15. [[CrossRef](#)]
38. Probst, B.L.; McCauley, L.; Trevino, I.; Wigley, W.C.; Ferguson, D.A. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405. *PLoS ONE* **2015**, *10*, e0135257. [[CrossRef](#)]
39. Li, Z.; Yang, Z.; Lapidus, R.G.; Liu, X.; Cullen, K.J.; Dan, H. IKK phosphorylation of NF- κ B at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. *Am. J. Cancer Res.* **2015**, *5*, 3098–3110.
40. Stamler, J.S.; Lamas, S.; Fang, F.C. Nitrosylation. The prototypic redox-based signaling mechanism. *Cell* **2001**, *106*, 675–683. [[CrossRef](#)]
41. Kim, J.; Won, J.S.; Singh, A.K.; Sharma, A.K.; Singh, I. STAT3 Regulation by S-Nitrosylation: Implication for Inflammatory Disease. *Antioxid. Redox Signal.* **2014**, *20*, 2514–2527. [[CrossRef](#)]
42. Reynaert, N.L.; Ckless, K.; Korn, S.H.; Vos, N.; Guala, A.S.; Wouters, E.F.M.; van der Vliet, A.; Janssen-Heininger, Y.M.W. Nitric oxide represses inhibitory κ B kinase through S-nitrosylation. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 8945–8950. [[CrossRef](#)]
43. Marcu, K.B.; Otero, M.; Olivotto, E.; Borzi, R.M.; Goldring, M.B. NF-kappaB signaling: Multiple angles to target OA. *Curr. Drug Targets* **2010**, *11*, 599–613. [[CrossRef](#)] [[PubMed](#)]
44. Jaiman, S.; Sharma, A.K.; Singh, K.; Khanna, D. Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy. *Eur. J. Clin. Pharmacol.* **2013**, *69*, 1863–1874. [[CrossRef](#)] [[PubMed](#)]
45. Sun, S.C. The noncanonical NF- κ B pathway. *Immunol. Rev.* **2012**, *246*, 125–140. [[CrossRef](#)] [[PubMed](#)]
46. Kanarek, N.; Ben-Neriah, Y. Regulation of NF- κ B by ubiquitination and degradation of the I κ Bs. *Immunol. Rev.* **2012**, *246*, 77–94. [[CrossRef](#)]

47. Liu, Y.; Zhu, P.; Wang, Y.; Wei, Z.; Tao, L.; Zhu, Z.; Sheng, X.; Wang, S.; Ruan, J.; Liu, Z.; et al. Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF- κ B and ERK/MAPK Signaling Pathways. *PLoS ONE* **2015**, *10*, e0123781. [[CrossRef](#)] [[PubMed](#)]
48. Wu, D.; Luo, N.; Wang, L.; Zhao, Z.; Bu, H.; Xu, G.; Yan, Y.; Che, X.; Jiao, Z.; Zhao, T.; et al. Hydrogen sulfide ameliorates chronic renal failure in rats by inhibiting apoptosis and inflammation through ROS/MAPK and NF- κ B signaling pathways. *Sci. Rep.* **2017**, *7*, 455. [[CrossRef](#)]
49. Liu, M.; Jia, Z.; Sun, Y.; Zhang, A.; Yang, T. A H₂S Donor GYY4137 Exacerbates Cisplatin-Induced Nephrotoxicity in Mice. *Mediat. Inflamm.* **2016**, *2016*, 1–10. [[CrossRef](#)]
50. Whiteman, M.; Perry, A.; Zhou, Z.; Bucci, M.; Papapetropoulos, A.; Cirino, G.; Wood, M.E. Phosphinodithioate and Phosphoramidodithioate Hydrogen Sulfide Donors. *Bile Acids Their Recept.* **2015**, *230*, 337–363. [[CrossRef](#)]
51. Lin, S.; Visram, F.; Liu, W.; Haig, A.; Jiang, J.; Mok, A.; Lian, D.; Wood, M.E.; Torregrossa, R.; Whiteman, M.; et al. GYY4137, a Slow-Releasing Hydrogen Sulfide Donor, Ameliorates Renal Damage Associated with Chronic Obstructive Uropathy. *J. Urol.* **2016**, *196*, 1778–1787. [[CrossRef](#)]
52. Meng, G.; Zhu, J.; Xiao, Y.; Huang, Z.; Zhang, Y.; Tang, X.; Xie, L.; Chen, Y.; Shao, Y.; Ferro, A.; et al. Hydrogen Sulfide Donor GYY4137 Protects against Myocardial Fibrosis. *Oxidative Med. Cell. Longev.* **2015**, *2015*, 1–14. [[CrossRef](#)] [[PubMed](#)]
53. Yu, F.; Zhao, J.; Tang, C.; Geng, B. Effect of synthesized GYY4137, a slowly releasing hydrogen sulfide donor, on cell viability and distribution of hydrogen sulfide in mice. *Beijing Da Xue Xue Bao. Yi Xue Ban J. Peking Univ. Health Sci.* **2010**, *42*, 493–497.
54. Ahangarpour, A.; Fard, A.A.; Gharibnaseri, M.K.; Jalali, T.; Rashidi, I. Hydrogen sulfide ameliorates the kidney dysfunction and damage in cisplatin-induced nephrotoxicity in rat. *Vet. Res. Forum Int. Q. J.* **2014**, *5*, 121–127.
55. Karimi, A.; Absalan, F.; Khorsandi, L.; Valizadeh, A.; Mansouri, E. Sodium hydrogen sulfide (NaHS) ameliorates alterations caused by cisplatin in filtration slit diaphragm and podocyte cytoskeletal in rat kidney. *J. Nephropathol.* **2017**, *6*, 150–156. [[CrossRef](#)]
56. Yuan, Y.; Zhu, L.; Li, L.; Liu, J.; Chen, Y.; Cheng, J.; Peng, T.; Lu, Y. S-Sulfhydration of SIRT3 by Hydrogen Sulfide Attenuates Mitochondrial Dysfunction in Cisplatin-Induced Acute Kidney Injury. *Antioxid. Redox Signal.* **2019**, *31*, 1302–1319. [[CrossRef](#)]
57. Francescato, H.D.C.; Cunha, T.M.; Costa, R.S.; Barbosa, F.; Boim, M.A.; Arnoni, C.P.; da Silva, C.G.A.; Coimbra, T.M. Inhibition of hydrogen sulphide formation reduces cisplatin-induced renal damage. *Nephrol. Dial. Transplant.* **2010**, *26*, 479–488. [[CrossRef](#)] [[PubMed](#)]
58. Otuntemur, A.; Ozbek, E.; Dursun, M.; Sahin, S.; Besiroglu, H.; Ozsoy, O.D.; Cekmen, M.; Somay, A.; Ozbay, N. Protective effect of hydrogen sulfide on gentamicin-induced renal injury. *Ren. Fail.* **2014**, *36*, 925–931. [[CrossRef](#)]
59. Dickey, D.T.; Wu, Y.J.; Muldoon, L.L.; Neuwelt, E.A. Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels. *J. Pharmacol. Exp. Ther.* **2005**, *314*, 1052–1058. [[CrossRef](#)]
60. Dugbartey, G.J.; Bouma, H.R.; Lobb, I.; Sener, A. Hydrogen sulfide: A novel nephroprotectant against cisplatin-induced renal toxicity. *Nitric Oxide* **2016**, *57*, 15–20. [[CrossRef](#)]
61. Tripatara, P.; Patel, N.S.; Collino, M.; Gallicchio, M.; Kieswich, J.; Castiglia, S.; Benetti, E.; Stewart, K.N.; Brown, P.A.; Yaqoob, M.M.; et al. Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. *Lab. Investig. J. Tech. Methods Pathol.* **2008**, *88*, 1038–1048. [[CrossRef](#)] [[PubMed](#)]
62. Xu, Z.; Prathapasinghe, G.; Wu, N.; Hwang, S.Y.; Siow, Y.L. Ischemia-reperfusion reduces cystathionine-beta-synthase-mediated hydrogen sulfide generation in the kidney. *American journal of physiology. Renal Physiol.* **2009**, *297*, F27–F35. [[CrossRef](#)] [[PubMed](#)]
63. King, A.L.; Lefer, D.J.; Howarth, F.C.; Sobhy, Z.H.H.; Parekh, K.; Yammahi, S.R.R.K.D.; Qureshi, M.A.; Adrian, T.E.; Adeghate, E. Cytoprotective actions of hydrogen sulfide in ischaemia-reperfusion injury. *Exp. Physiol.* **2011**, *96*, 840–846. [[CrossRef](#)] [[PubMed](#)]
64. Tripatara, P.; Patel, N.S.A.; Brancaleone, V.; Renshaw, D.; Rocha, J.; Sepodes, B.; Mota-Filipe, H.; Perretti, M.; Thiemeermann, C. Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: An in vivo study. *Eur. J. Pharmacol.* **2009**, *606*, 205–209. [[CrossRef](#)] [[PubMed](#)]

65. Song, K.; Wang, F.; Li, Q.; Shi, Y.B.; Zheng, H.F.; Peng, H.; Shen, H.Y.; Liu, C.F.; Hu, L.F. Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy. *Kidney Int.* **2014**, *85*, 1318–1329. [[CrossRef](#)] [[PubMed](#)]
66. Zhou, Y.; Zhu, X.; Wang, X.; Peng, Y.; Du, J.; Yin, H.; Yang, H.; Ni, X.; Zhang, W. H₂S alleviates renal injury and fibrosis in response to unilateral ureteral obstruction by regulating macrophage infiltration via inhibition of NLRP3 signaling. *Exp. Cell Res.* **2020**, *387*, 111779. [[CrossRef](#)]
67. Jung, K.J.; Jang, H.S.; Kim, J.I.; Han, S.J.; Park, J.W.; Park, K.M. Involvement of hydrogen sulfide and homocysteine transsulfuration pathway in the progression of kidney fibrosis after ureteral obstruction. *Biochim. Biophys. Acta* **2013**, *1832*, 1989–1997. [[CrossRef](#)]
68. Zhou, X.; Feng, Y.; Zhan, Z.; Chen, J. Hydrogen Sulfide Alleviates Diabetic Nephropathy in a Streptozotocin-induced Diabetic Rat Model. *J. Biol. Chem.* **2014**, *289*, 28827–28834. [[CrossRef](#)]
69. Yuan, P.; Xue, H.; Zhou, L.; Qu, L.; Li, C.; Wang, Z.; Ni, J.; Yu, C.; Yao, T.; Huang, Y.; et al. Rescue of mesangial cells from high glucose-induced over-proliferation and extracellular matrix secretion by hydrogen sulfide. *Nephrol. Dial. Transplant.* **2011**, *26*, 2119–2126. [[CrossRef](#)]
70. Prathapasinghe, G.A.; Siow, Y.L. Detrimental role of homocysteine in renal ischemia-reperfusion injury. *Am. J. Physiol. Physiol.* **2007**, *292*, F1354–F1363. [[CrossRef](#)]
71. Prathapasinghe, G.A.; Siow, Y.L.; Xu, Z. Inhibition of cystathionine-beta-synthase activity during renal ischemia-reperfusion: Role of pH and nitric oxide. *American journal of physiology. Renal Physiol.* **2008**, *295*, F912–F922. [[CrossRef](#)]
72. Li, L.; Whiteman, M.; Guan, Y.Y.; Neo, K.L.; Cheng, Y.; Lee, S.W.; Zhao, Y.; Baskar, R.; Tan, C.H.; Moore, P.K. Characterization of a Novel, Water-Soluble Hydrogen Sulfide-Releasing Molecule (GYY4137). *Circulation* **2008**, *117*, 2351–2360. [[CrossRef](#)] [[PubMed](#)]
73. Sun, H.; Zhu, X.; Zhou, Y.; Cai, W.; Qiu, L. C1q/TNF-Related Protein-9 Ameliorates Ox-LDL-Induced Endothelial Dysfunction via PGC-1alpha/AMPK-Mediated Antioxidant Enzyme Induction. *Int. J. Mol. Sci.* **2017**, *18*, 1097. [[CrossRef](#)] [[PubMed](#)]
74. Sun, H.; Zhu, X.; Lin, W.; Zhou, Y.; Cai, W.; Qiu, L. Interactions of TLR4 and PPAR γ , Dependent on AMPK Signalling Pathway Contribute to Anti-Inflammatory Effects of Vaccariae Hypaphorine in Endothelial Cells. *Cell. Physiol. Biochem.* **2017**, *42*, 1227–1239. [[CrossRef](#)] [[PubMed](#)]
75. Jiang, Y.; Liu, J.; Zhou, Z.; Liu, K.; Liu, C. Diosmetin Attenuates Akt Signaling Pathway by Modulating Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kappaB)/Inducible Nitric Oxide Synthase (iNOS) in Streptozotocin (STZ)-Induced Diabetic Nephropathy Mice. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* **2018**, *24*, 7007–7014.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).